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Abstract
Background: Dairy products are a major contributor to dietary SFA. Partial replacement of milk SFA with
unsaturated fatty acids (FAs) is possible through oleic-acid rich supplementation of the dairy cow diet. To assess
adherence to the intervention of SFA-reduced, MUFA-enriched dairy product consumption in the RESET
(REplacement of SaturatEd fat in dairy on Total cholesterol) study using 4-d weighed dietary records, in addition to
plasma phospholipid FA (PL-FA) status.
Methods: In a randomised, controlled, crossover design, free-living UK participants identified as moderate risk for
CVD (n = 54) were required to replace habitually consumed dairy foods (milk, cheese and butter), with study
products with a FA profile typical of retail products (control) or SFA-reduced, MUFA-enriched profile (modified), for
two 12-week periods, separated by an 8-week washout period. A flexible food-exchange model was used to
implement each isoenergetic high-fat, high-dairy diet (38% of total energy intake (%TE) total fat): control (dietary
target: 19%TE SFA; 11%TE MUFA) and modified (16%TE SFA; 14%TE MUFA).
Results: Following the modified diet, there was a smaller increase in SFA (17.2%TE vs. 19.1%TE; p < 0.001) and
greater increase in MUFA intake (15.4%TE vs. 11.8%TE; p < 0.0001) when compared with the control. PL-FA analysis
revealed lower total SFAs (p = 0.006), higher total cis-MUFAs and trans-MUFAs (both p < 0.0001) following the
modified diet.
Conclusion: The food-exchange model was successfully used to achieve RESET dietary targets by partial
replacement of SFAs with MUFAs in dairy products, a finding reflected in the PL-FA profile and indicative of
objective dietary compliance.
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Background
Cardiovascular diseases (CVD) are one of the leading
causes of mortality in the UK [1]. As a result of the clear
link between a high intake of SFAs and elevated LDL-
cholesterol concentrations, dietary guidelines for CVD
prevention advocate reducing SFA intake to ≤10% of
total energy (%TE) [2, 3]. Despite recommendations, the
UK adult population still exceeds the target for dietary
SFA intake, with a mean intake of 12.1%TE [4].
Dairy products are major sources of dietary SFA and ac-
count for up to 35% of total UK SFA intake [4] and there-
fore reducing consumption of regular-fat dairy foods or
replacing them with lower fat or fat-free alternatives is
often advised [5, 6]. However, prospective studies have not
presented consistent evidence for an adverse link between
higher consumption of milk and dairy products and in-
creased risk of CVD, regardless of milk fat content [7–10].
Furthermore, this rationalisation does not acknowledge the
complex nature of the dairy food matrix, which may be
fundamental to cardiovascular health [11]. Dairy fat con-
tains a complex mixture of fatty acids (FA) including SFAs,
MUFAs, PUFAs, trans-fatty acids (TFAs) and branched-
chain FAs [12, 13]. Furthermore, milk is rich in micronutri-
ents and bioactive peptides, which have been reported to
exert cardio-protective effects [14, 15].
While the findings of some recent epidemiological stud-
ies have challenged the traditional link between SFA and
coronary heart disease risk, and mortality [16–18], it is im-
portant to consider the macronutrient that replaces energy
from dietary SFA [18, 19]. There is evidence from a ran-
domized controlled trial (RCT) that replacement of SFA
with PUFA had minimal but increased effects on CHD
mortality [20]. However a more recent systematic review
and meta-analysis of RCT suggests that lowering SFA in-
take could reduce cardiovascular events by 17%, with SFA
replacement with PUFA estimated to reduce these events
by 27% [21]. Despite these apparent discrepancies, current
US and EU dietary guidelines recommend reduction of
SFA and replacement with PUFA and/or MUFA respect-
ively [22, 23]. In support of the latter review and dietary
recommendations, a RCT illustrated that replacing SFA
with n-6 PUFA for 16-weeks induced a reduction in serum
concentration of LDL-cholesterol (a major risk factor for
CVD) by 13.6%, with a comparable reduction of 11.3% on
replacement of SFA with MUFA [19].
It is well documented that partial replacement of milk
SFA with unsaturated FAs, predominantly in the form of
MUFA, through supplementation of the dairy cow diet
with plant oils or oil seeds is feasible [24–26]. At a popula-
tion level, this initiative could provide a sustainable means
of reducing SFA in dairy products, whilst limiting the
entry of SFA into the wider food chain. While limited evi-
dence from human studies suggest that consumption of
dairy products with a modified FA profile may beneficially
impact on CVD risk, there has been a heavy reliance on
fasting lipid biomarkers as sole predictors of risk [27]. Fur-
ther research is needed to elucidate whether FA-modified
dairy product consumption has a differential effect on
more novel risk markers, including endothelial function,
arterial stiffness, systemic inflammation and ambulatory
blood pressure, when compared with dairy products of
typical milk FA composition [15, 27].
The REplacement of SaturatEd fat in dairy on Total
cholesterol (RESET) study was conducted to investigate
the chronic and acute effects of two iso-energetic high-
fat, high-dairy diets, which varied in FA composition, on
traditional and novel cardiometabolic risk markers in
free-living individuals. It is important to evaluate strat-
egies employed for the achievement of dietary targets in
controlled human intervention studies [28]. The purpose
of the current paper is to describe the RESET dietary ex-
change strategy that was developed to enable manipula-
tion of the FA profile of the diet over two 12-week
periods, through the use of SFA-reduced, MUFA-
enriched (modified) dairy products and matched control
dairy foods with a FA profile typical of retail products.
Although it is recognised that specific plasma FA levels
can be indicative of dietary FA consumption, the com-
position of the plasma phospholipid FA (PL-FA) fraction
is believed to be a good biomarker of FA intake over re-
cent days to weeks and an objective indicator of dietary
compliance [29–31]. Thus, this paper aims to report the
chronic dietary intervention food-exchange model and
the compliance to the FA-modified and control dietary
exchange periods using 4-d weighed dietary records,
self-reported daily tick-sheets and PL-FA.
Materials and methods
Study participants and design
The RESET study was a double-blinded, randomised,
controlled, crossover designed trial registered at Clinical-
trials.Gov as: NCT02089035. The study was given a
favourable ethical opinion for conduct by the University
of Reading’s Research Ethics Committee (13/43) and was
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conducted according to the guidelines of the Declaration
of Helsinki. All participants provided written informed
consent prior to study entry.
Men and women aged 25–70 years were recruited
from the Berkshire area of the UK in three cohorts
between February 2014 and April 2016. A modified
Framingham risk prediction algorithm was employed to
identify individuals with moderate CVD risk [31, 32]. To
meet inclusion criteria, participants were required to
have ≥ 2 CVD risk points, a score that suggested a 50%
greater risk of CVD development than the population
mean [32]. Briefly, this score was calculated based on
the existence of single or multiple CVD risk factors,
including elevated fasting total cholesterol, glucose,
systolic/diastolic blood pressure, low HDL-cholesterol,
overweight/obesity or a family history of myocardial in-
farction. Potential participants were also required to meet
the following inclusion criteria: BMI 19–32 kg/m2; blood
pressure <160/100 mmHg; total cholesterol <8 mmol/L;
haemoglobin: >125 g/L for women and 135 g/L for
men; normal liver and kidney function; not pregnant
or lactating; no dietary supplementation; no lactose or
dairy intolerances/allergies; not taking medication for
hyperlipidaemia, hypertension, hypercoagulation or inflam-
matory conditions; no diagnosis of myocardial infarction,
stroke or diabetes; participating in <20 min × 3 times/week
of vigorous aerobic activity and not consuming excessive
amounts of alcohol (men: <21 units/week; women: <14
units/week). If known not to interfere with study out-
comes, participants continued to take their regular pre-
scribed medication, without changes in dosage, for the
duration of the study.
Study foods
The FA composition of the dairy products (including ru-
minant cis and TFAs), along with the methods for their
production, will be described in detail elsewhere (Kliem
KE, Humphries DJ, Markey O, Vasilopoulou D, Fagan
CC, Grandison AS, Todd S, Givens DI, Lovegrove JA:
Food chain approach to lowering saturated fat in milk
and dairy products: the RESET study, submitted). Based
on a similar feeding strategy, it was estimated that our
bovine intervention would increase cis-MUFA in the
milk from 20 to 30 g/100 g FA, while reducing SFA from
70 to 55–60 g/100 g FA [33]. Briefly, the diet of re-
cruited Holstein-Friesian cows was supplemented with
approximately 1 kg high-oleic sunflower oil (AAK Ltd.,
Hull, East Yorkshire, UK) per cow per day for a ≥ 28-d
period to produce milk which had a portion of SFA re-
placed with MUFA. Subsequently, raw milk was used to
produce SFA-reduced, MUFA-enriched (modified) ultra
high temperature (UHT) milk, Cheddar cheese and butter.
Raw milk, provided by Arla UK Plc (Taw Valley Creamery,
North Tawton, UK), was used to produce control UHT
milk. Control Cheddar cheese and butter, with a FA profile
typical of retail products, were also supplied by Arla UK
Plc (Taw Valley Creamery, North Tawton, UK).
Dietary intervention
The technique of minimization, controlling for gender,
age, BMI and total cholesterol was used to randomly al-
locate participants to one of two groups in the study,
with Group 1 being assigned to receive Diet A (Modified)
and then Diet B (Control) during their first and second
dietary intervention periods, respectively and vice-versa
for Group 2 [34]. In each group, participants completed
two 12-week dietary intervention periods, separated by an
8-week washout period. One dietary intervention was an
iso-energetic high-fat daily dietary exchange (dietary
target: 38%TE total fat) which was achieved by replacing
habitual dairy foods, cooking oil and snacks with SFA-
reduced, MUFA-enriched UHT milk, Cheddar cheese and
butter (modified). The second dietary intervention used
matched products with a FA profile typical of retail prod-
ucts (control). The dietary exchange periods were rich in
dairy foods and were designed to give diets of equal fat
content that varied in SFA and MUFA composition. The
dietary target intake for total fat was 38%TE in both diets,
with specific dietary FA targets for the control (19%TE
SFA and 11%TE MUFA) and modified diets (16%TE SFA
and 14%TE MUFA).
Measurements of circulating total cholesterol, com-
posed of LDL and HDL-cholesterol (primary outcome),
and other established and novel CVD and cardiometa-
bolic risk markers were assessed prior to and after each
dietary intervention period (chronic study). This manu-
script will present the 4-d weighed dietary records, tick-
sheet records, anthropometric measures, and PL-FA
analysis to assess dietary compliance. The other clinical
outcome measures from the RESET study will be pub-
lished elsewhere.
Food-exchange model
The RESET study food-exchange strategy for reducing
SFA intake was designed based on a model adapted from
both the Dietary Intervention and Vascular Function (DI-
VAS) study and the Reading, Imperial, Surrey, Cambridge,
and Kings (RISCK) study [31, 35], which were based on the
National Diet and Nutrition Survey (NDNS) for adults
(aged 19–64 years) [36]. The mean habitual energy, total
fat, SFA, MUFA and PUFA intakes of participants from the
RISCK study were used [35], with additional TFA
data obtained from the DIVAS study [31], as these
dietary data represented the intake of UK adults who
were at increased or moderate CVD risk. Added oils,
added fats (butter and spreads), milk, cheese as well
as sweet and savoury snacks were identified as ‘ex-
changeable dietary fat’ sources which could be
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removed from the diet and replaced with study foods.
The total contribution of these ‘exchangeable fat’ food
groups to mean daily energy, fat and FA intake were
estimated, based on mean population data from the
2000/2001 NDNS ‘percentage contribution of types of
foods’ (Table 1). The total exchangeable fat was sub-
tracted from the RISCK/DIVAS study habitual energy,
total fat and FA intake to calculate non-modifiable fat in-
take. This was employed to form the backbone of the
food-exchange model, onto which the RESET study foods
could be added to create two iso-energetic dietary ex-
change periods of dairy products that varied in FA com-
position (Table 2).
Implementation of intervention diets
After completing baseline visits (i.e. at the beginning of
each intervention period), participants were provided
with 1:1 dietary advice on how to replace dietary fat
sources in their habitual diets (e.g. added oils, milk,
cheese, sweet and savoury snacks) with the study dairy
foods. They were also given dietary guidelines and recipe
suggestions to take home. Care was taken to ensure that
no study visits were arranged during or immediately
after the Christmas period (mid-December to mid-
January). Where it was not feasible to avoid holidays and
business trips during intervention periods, participants
were given instructions on how to travel with the study
products. This was made more convenient by providing
UHT milk that did not require refrigeration. Further-
more, participants were provided with frozen butter and
were advised that they could it frozen during transit,
with the use of ice packs. Products were provided in
plain packaging and were only identifiable by a code (A
or B), to ensure that participants and researchers
remained blinded to the intervention arms.
At the beginning of each intervention period, partici-
pants were given adequate study dairy foods for a 4-week
period. They attended the Hugh Sinclair Unit of Human
Nutrition for a food collection visit at weeks 4 and 8.
During this visit, adherence to the dietary intervention
was assessed by reviewing completed tick-sheet records
and any issues were discussed and resolved. In addition,
investigators recorded the participant’s weight and any
changes ≥ ± 1 kg of baseline, were addressed through
advice to alter snack, meat and/or carbohydrate intake.
Participants were asked to maintain their habitual physical
activity levels during each intervention period. At the end
of the first intervention period, participants were asked to
return unopened, leftover study products and were asked
not to consume any leftover study products for the dur-
ation of the washout period.
Assessment of dietary intake
Participants received verbal and written instructions by
the investigators for recording 4-d weighed dietary re-
cords approximately 2 week before the first study visit
(week 0). Investigators also provided participants with
examples of completed diaries, including how to record
recipes, and digital scales for recording food intake. Ex-
ceptions for weighing included food consumed outside
of the home. On these occasions, portion-size images
were used to estimate consumed portions and subse-
quently quantified using published food portion tables
[37]. Participants completed diet diaries on four separate
occasions (weeks 0, 11, 19 and 31): habitual diet intake
was represented from baseline diet diaries (weeks 0 and
Table 1 The RESET food-exchange modela
Total energy Total fat SFA MUFA TFA PUFA
(MJ/d)
Total habitual intake (including alcohol)b, g/d 8.25 80.1 29.6 26.6 1.0 13.1
Total habitual intake, %TE 36.6 13.5 12.1 0.4 6.0
Exchangeable fat intake
Added oils, g/d 0.35 8.5 0.8 3.3 4.0
Added fats (butter and spreads), g/d 0.35 8.6 3.3 2.9 0.2 1.7
Milk, g/d 0.45 4.0 2.4 1.0 0.0 0.3
Cheese, g/d 0.25 4.5 2.8 1.0 0.1 0.1
Sweet and savoury snacks, g/dc 0.87 10.0 4.4 3.4 0.1 0.6
Total exchangeable fat intake, g/d 2.27 35.5 13.6 11.6 0.4 6.6
Total exchangeable fat intake adjusted for habitual intake, g/d 2.22 38.5 14.4 12.5 0.4 7.3
Non-exchangeable fat intake, g/d 6.03 41.7 15.3 14.1 0.6 5.9
TFA trans-fatty acids, %TE percentage of total energy
aAdapted from Weech et al. [31]
bMean daily dietary intakes (total energy, total fat, SFA, MUFA and PUFA) from a population with increased cardiovascular disease risk [35]. Mean daily dietary TFA
intake from a population at moderate cardiovascular disease risk [31]
cIncluded buns, cakes, pastries, potato chips and chocolate confectionary
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19), while diaries completed during weeks 11 and 31
represented participant compliance to the intervention
diets. Prior to visit 1, food intake was recorded on three
weekdays and one weekend day. The same days were re-
peated for subsequent diaries. Assessment of completion
of the diaries was undertaken by the investigators during
study visits. If necessary, additional information was re-
quested to facilitate precise data entry.
Food diaries were analysed using the NDS Nutrient
Database or McCance and Widdowson’s (MW7) nutrient
databank contained within the nutrient analysis software
Dietplan 7 (Forestfield Software Ltd.). The nutritional con-
tent of the control and modified dairy products is pre-
sented in Kliem et al. (Kliem KE, Humphries DJ, Markey
O, Vasilopoulou D, Fagan CC, Grandison AS, Todd S,
Givens DI, Lovegrove JA: Food chain approach to lower-
ing saturated fat in milk and dairy products: the RESET
study, submitted). Energy and macronutrient content
(Group 1 nutritional analysis) was performed in duplicate
by SGS UK Ltd. (Ealing, London, UK; ISO 17025 accre-
dited laboratory). Analysis of sodium, calcium, magnesium
and phosphorus content was conducted in duplicate by
inductively coupled plasma-optical emission spectrometry
at Quaternary Scientific (QUEST, School of Archaeology,
Geography and Environmental Science, University of
Reading, Reading, UK). Extracted lipids from milk, cheese
and butter samples were analysed in triplicate for FA com-
position using a GC-flame ionisation detection method
[38]. A conversion factor of 0.933 was used to estimate
the proportion of FAs in the total fat content of each dairy
product [39]. Subsequently, the quantity of SFA, MUFA,
TFA and PUFA were calculated per daily portion of each
study dairy product (g/d). Nutrient composition of the
study products was entered manually in Dietplan. For the
purpose of analysis, the mean daily intakes of energy and
macronutrients were recorded and the %TE was cal-
culated to adjust for energy intake (EI). Dietary fibre
intake was defined using the Association of Official
Analytic Chemists (AOAC) method [40].
Assessment of underestimation of energy intake
Determination of possible underestimation of dietary EI
was assessed for each participant. Basal metabolic rate,
based on age, gender and body weight, was estimated using
the Henry equation [41]. A sedentary lifestyle was repre-
sented by a physical activity level score of 1.2 [31, 42].
The Goldberg lower 95% confidence limit was calcu-
lated as <1.132 using the CV recommended by Black
Table 2 Replacement model for diets containing control and modified dairy products for use in the RESET studya
Quantity Total energy Total fat SFA MUFA TFAb PUFA
(g/d) (MJ/d)
Non-exchangeable fat intake, g/d 6.03 41.7 15.3 14.1 0.5 5.9
Control dietary exchange
Exchangeable fat intakesc
Butter, g/d 21.5 0.65 17.4 11.1 4.5 0.7 0.6
Cheese, g/d 45.0 0.76 15.1 10.2 3.5 0.5 0.4
Milk, g/d 340.0 0.75 8.6 5.7 2.1 0.3 0.3
Total intake, g/d 8.19 82.8 42.3 24.2 2.0 7.2
Total intake, %TE 38.1 19.4 11.1 0.9 3.3
Target intake, %TE 38.0 19.0 11.0 0.9
Modified dietary exchange
Exchangeable fat intakes
Butter 25.1 0.76 20.4 10.2 8.1 2.1 0.7
Cheese, g/d 45.0 0.69 12.6 6.3 5.0 1.4 0.4
Milk, g/d 340 0.79 8.8 4.4 3.6 0.9 0.3
Total intake, g/d 8.27 83.4 36.0 30.8 4.9 7.3
Total intake, %TE 38.0 16.4 14.0 2.1 3.3
Target intake, %TE 38.0 16.0 14.0 2.0
Mean difference between dietary exchange periods, %TE −0.6 6.2 −6.7 −2.9 −0.2
The FA composition of dairy products was determined using a GC-flame ionisation detection method [38], with a conversion factor of 0.933 used to estimate the
proportion of FAs in the total fat content of each product [39]
%TE, percentage of total energy
aTotal intake is the sum of exchangeable and non-exchangeable intakes based on MJ/d for energy and grams/d for FAs
bTotal TFA intake (%TE) is calculated based on recorded energy intake at baseline (MJ/d) in Weech et al. [31]
cEnergy and fat content of the dairy products is based on nutritional analysis conducted by SGS United Kingdom Ltd. (Ellesmere Port, Cheshire)
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(n = 51; 4 d) and was used to identify under-reporters
of EI [42].
Assessment of dietary compliance
As outlined in Table 2, participants were required to con-
sume the minimum daily portions of each of the following
study products: 340 g/d milk, 45 g/d cheese and 21.5 or
25.1 g/d of control or modified butter, respectively. This
ensured that the intervention diets were iso-energetic and
contained equal quantities of dairy fat (38%TE total fat;
approx. 41 g/d). As a means of monitoring compliance
with each study product type, participants were required
to complete tick-sheet records on a daily basis throughout
each 12-week dietary intervention period. Participants
were given the option of marking the tick box if they had
consumed the required portion size or could choose to
record the actual weight of the product consumed. In
order to calculate dietary compliance, one point was sub-
tracted for each day that participants had not consumed a
study product. These points were summed over each
intervention period and were used to calculate percentage
dietary compliance for each product type.
Assessment of anthropometrics
Participants were requested to fast overnight for 12 h
before each clinical visit, following consumption of a
standardised low-fat evening meal (<1.46 MJ; < 7 g total
fat) and low-nitrate water (Buxton Mineral Water, Nestlé
Waters, Buxton, UK). At weeks 0, 12, 20 and 32, fasted
measurements of BMI and waist circumference were re-
corded. Height was measured to the nearest 0.1 cm
using a wall-mounted stadiometer (screening visit only).
BMI was calculated using the Tanita BC-418 digital scale
(Tanita Europe), under normal settings (standard body
type and −1 kg for clothing) with participants wearing
light clothing. Waist circumference was measured by a
trained investigator, in triplicate, halfway between the
iliac crest and the lowest rib margin to the nearest
0.5 cm [31].
Assessment of plasma phospholipid fatty acid status
Fasting blood samples were collected into lithium hep-
arin tubes for determination of PL-FA status prior to
and after each 12-week intervention period (week 0, 12,
20, 32). Chilled samples were centrifuged at 3000 rpm
(1700 g) for 15 min at 4 °C and plasma stored at −80 °C
until subsequent extraction and analysis.
Sequential multipurpose sampler systems (Gerstel
GmbH & Co. KG, Mülheim an der Ruhr, Germany) were
employed for automated sample preparation and deriva-
tization of FAs from the phospholipid fraction at the
MRC Human Nutrition Research, Cambridge, as previ-
ously described [43]. The phospholipid fraction was iso-
lated from plasma using solid phase extraction on
Na2SO4 50 mg/NH2 100 mg SPE cartridges (BE Gerstel;
Agilent Technologies) and the FAME were produced
from the phospholipid fraction according to the method
published by Burge et al. [44]. The FAMEs were sepa-
rated using a 30 m capillary column (HP-88; Agilent
Technologies, Cheshire, UK) and detected using flame
ionization. Results were expressed as molar percentage
of total PL-FAs (mol%).
Power calculation and statistical analyses
A total number of 54 participants were required for the
chronic study to have sufficient power to detect a signifi-
cant change in the primary and key secondary outcome
measures. The primary outcome (serum total choles-
terol, composed of LDL and HDL-cholesterol) was pre-
dicted to result in a ~0.3 mmol/L reduction with a
population mean of 4.54 ± 0.5 mmol/L, with a power of
80% at P < 0.05, allowing for a 15% dropout rate. The
chronic study was also powered to detect a 1.5% inter-
group difference in the key secondary outcome measure,
endothelial-dependent flow-mediated dilatation, with a
power of 80% at p < 0.05 [45]. However, this paper is
reporting on the food-exchange model and compliance
to our high-fat, high-dairy interventions, which varied in
FA composition.
Weighed dietary records, anthropometrics and PL-FA
were analyzed using mixed models. Change-from-baseline
for each variable of interest were modelled. Fixed effects
included in the model were baseline values of the assessed
variable, period, treatment, age, gender and BMI. All data
were checked for normality and log transformed, if neces-
sary. Participants were included as a fixed effect. There
were no effects of the period in the model for any out-
come measure.
Paired t-tests were used to assess differences in mean
dietary compliance scores, as assessed by tick-sheet re-
cords, and underestimation of EI between the control and
modified dietary interventions. For confirmation that our
randomization approach was effective, differences in base-
line characteristics between participants randomly assigned
to the control and modified dietary intervention periods
were assessed using independent t-tests and Chi-square
tests for continuous and categorical variables, respectively.
Statistical analyses were conducted using the SAS
university edition statistical software (version 9.4; SAS
Institute lnc., Cary, NC, USA). Results are presented
as means and standard error of the mean (SEM). Dif-
ferences were considered significant at p ≤ 0.01 to ac-
count for multiplicity.
Orthogonal partial least squares discriminant analysis
(PLS-DA) was applied to identify patterns between vari-
ables in our PL-FA dataset and summarised it by redu-
cing the number of dimensions or components [46].
Measured PL-FA concentrations of 36 individual FAs
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were subjected to orthogonal PLS-DA at: 1) baseline
and 2) post-intervention using Metabolanalyst 3.0 [46].
The R2Y and Q2 values represented the goodness of fit
and predictability of the models, respectively. Significance
of the models were tested using 1000 permutations.
Results
Participant flow through the study is illustrated in Fig. 1. Of
the 74 participants who were randomly assigned and com-
menced the study, 54 (31 males and 23 females) completed
the study. Participants continued to take their regular pre-
scribed medication for the duration of the study (n = 2
levothyroxine for hypothyroidism; n = 1 proton pump in-
hibitor for heartburn; n = 1 hormone replacement therapy
for menopausal symptom relief; n = 1 tricyclic antidepres-
sant for depression; n = 2 fluticasone and salmeterol for
mild asthma; n = 1 etonogestrel contraceptive implant
and n = 1 levonorgestrel-releasing intrauterine contra-
ceptive device). The breakdown of the ethnicity of the
study group was as follows: White, 89% (n = 48);
Asian, 4% (n = 2); Black, 4% (n = 2) and Chinese/Far
Eastern, 4% (n = 2). There were no significant differ-
ences between participants randomly assigned to
Groups 1 and 2 at baseline (Additional file 1: Table S1).
Two participants were excluded from the dietary analysis
due to insufficient data.
Dietary analysis
Recorded dietary intake at baseline and following diets
that incorporated the control and modified dairy prod-
ucts (post-intervention) are shown in Table 3. In agree-
ment with target intakes (Table 2), significant treatment
Fig. 1 Flow of participants through the different stages of the RESET study
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effects were evident for dietary intakes of SFA and
MUFA. Following introduction of the modified diet,
there was a smaller increase in SFA and greater increase
in MUFA and TFA, relative to baseline, when compared
with the control.
Underestimation of energy intake
Based on the assumption that participants were in en-
ergy balance, it was estimated that recorded EI were
underestimated for 35 and 22% of participants at base-
line and post-intervention, respectively. Underestimation
of EI was not considered further in the mixed model
analysis.
Dietary compliance
On the basis of tick-sheet records, mean daily intake (±
SEM) of the dairy products across each 12-week dietary
exchange was as follows: milk (control: 343.5 ± 1.8;
modified: 347.8 ± 2.8 g/d), cheese (control: 46.5 ± 0.6;
modified: 45.9 ± 0.4 g/d) and butter (control: 22.0 ± 0.2;
modified: 25.6 ± 0.3 g/d). Mean daily dietary compliance
did not vary according to treatment: milk (control:
96.6 ± 0.01; modified: 96.5 ± 0.01%; p = 0.92), cheese (con-
trol: 96.6 ± 0.01; modified: 96.8 ± 0.01%; P = 0.83) and but-
ter (control: 96.5 ± 0.01; modified: 97.0 ± 0.01%; p = 0.70).
Anthropometric measures
Relative to baseline, there was no significant treatment
effect for BMI (control: 25.8 ± 0.5 vs. 26.2 ± 0.5 kg/m2
for baseline vs. post-intervention; modified: 25.8 ± 0.5 vs.
25.9 ± 0.5 kg/m2; p = 0.13) or waist circumference (con-
trol: 88.9 ± 1.4 vs. 89.8 ± 1.5 cm; modified: 89.3 ± 1.5 vs.
89.1 ± 1.5 cm; p = 0.53).
Plasma phospholipid FA status
After the 12-week intervention, there were significant
differences in PL-FA composition between the modified
and control groups (p ≤ 0.01). Consumption of the
modified dairy products led to a small but significant
decrease in abundance of total SFAs from baseline
(change: −0.60 ± 0.21 mol%) vs. control (change: 0.01 ±
0.17 mol%) (Table 4). Following the modified diet, there
were significant increases in cis-MUFAs and trans-
MUFAs from baseline vs. control (Table 4). There was a
minor increase in the abundance of 16:0 from baseline fol-
lowing the control diet (change: 0.16 ± 0.13 mol%), while a
decrease from baseline was evident following the modified
diet (change: −0.46 ± 0.15 mol%) (Fig. 2b). Compared with
baseline, 18 : 1cis-9 and 18 : 1trans-9 increased following
the modified diet vs. control (Fig. 2b). Following the con-
trol diet, there was a significant increase in 20 : 3n-6 vs.
the modified diet.
Orthogonal Partial Least Square Discriminant analysis of
plasma phospholipid FA data
For the baseline PLS-DA, the first component represent-
ing the maximum differentiation between the two diets
represented 4.7% of variation and was retained to
Table 3 Recorded dietary intake at baseline (week 0) and following diets that incorporated the control and modified dairy products
(week 12) in adults at moderate cardiovascular disease risk and target fatty acid intakesa
Control Modified
Baseline Post Tb Δ Baseline Post T Δ pc
Energy, MJ/d 8.5 ± 0.4 9.0 ± 0.3 0.5 ± 0.3 8.2 ± 0.3 9.2 ± 0.4 1.0 ± 0.4 0.60
Total fat, %TE 36.5 ± 0.8 39.5 ± 0.7 38.0 3.0 ± 0.9 36.1 ± 0.8 41.1 ± 0.8 38.0 5.0 ± 1.1 0.03
SFA, %TE 13.9 ± 0.5 19.1 ± 0.4 19.0 5.2 ± 0.6 14.2 ± 0.5 16.9 ± 0.4 16.0 2.7 ± 0.6 <0.001
MUFA, %TE 11.9 ± 0.4 11.8 ± 0.3 11.0 −0.1 ± 0.3 11.7 ± 0.4 15.3 ± 0.4 14.0 3.6 ± 0.5 <0.0001
n-6 PUFA, %TE 4.6 ± 0.2 3.3 ± 0.2 −1.3 ± 0.2 3.9 ± 0.2 3.4 ± 0.2 −0.5 ± 0.2 0.08
n-3 PUFA, %TE 0.8 ± 0.1 0.6 ± 0.0 −0.2 ± 0.1 0.7 ± 0.0 0.6 ± 0.0 −0.1 ± 0.1 0.34
Total PUFA, %TE 5.8 ± 0.4 4.4 ± 0.5 −1.4 ± 0.3 4.6 ± 0.2 4.0 ± 0.2 −0.4 ± 0.2 0.14
TFA, %TE 1.0 ± 0.1 1.3 ± 0.1 0.3 ± 0.1 0.9 ± 0.1 2.5 ± 0.1 1.6 ± 0.1 <0.0001
Protein, %TE 16.3 ± 0.5 16.1 ± 0.4 −0.2 ± 0.5 16.9 ± 0.5 16.2 ± 0.3 −0.7 ± 0.6 0.80
Carbohydrates, %TE 46.3 ± 0.9 43.3 ± 0.9 −3.0 ± 0.9 46.6 ± 1.3 42.2 ± 1.0 −4.4 ± 1.5 0.19
Alcohol, %TE 3.1 ± 0.5 3.1 ± 0.5 0.0 ± 0.4 2.9 ± 0.5 2.7 ± 0.4 −0.2 ± 0.5 0.35
Dietary fiber (AOAC), g/d 20.4 ± 1.1 22.0 ± 1.1 1.6 ± 0.9 20.2 ± 1.1 19.4 ± 1.1 −0.8 ± 1.2 0.03
Sodium, g/d 2.7 ± 0.2 2.2 ± 0.1 −0.5 ± 0.1 2.5 ± 0.2 1.9 ± 0.1 −0.6 ± 0.1 0.03
Participant was included as a random effect. p ≤ 0.01 deemed as significant
AOAC Association of Official Analytic Chemists, %TE percentage of total energy
aValues are means ± SEM. Dietary intakes estimated from 4-d weighed dietary records at baseline (week 0) and after intervention (week 12)
bTarget FA intakes for the control and modified dietary exchange periods
cOverall effect of treatment based on change-from-baseline was calculated by mixed model analysis, with adjustments made for fixed effects of baseline values of
the assessed variable, period, treatment, age, gender and BMI
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Table 4 Plasma phospholipid fatty acids at baseline (week 0) and following diets that incorporated the control and modified dairy
products (week 12) in adults at moderate cardiovascular disease riska
Control Modified
mol% Baseline Post Δ Baseline Post Δ pb
SFAs
11:0 0.0000 ± 0.0008 0.0013 ± 0.0008 0.0000 ± 0.0011 0.0000 ± 0.0011 0.0002 ± 0.0000 0.0025 ± 0.0010 0.35
12:0 0.0230 ± 0.0018 0.0242 ± 0.0015 0.0012 ± 0.0019 0.0245 ± 0.0000 0.0225 ± 0.0000 0.0019 ± 0.0016 0.22
13:0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.16
14:0 0.35 ± 0.01 0.42 ± 0.02 0.07 ± 0.02 0.35 ± 0.02 0.38 ± 0.02 0.03 ± 0.01 0.04
15:0 0.23 ± 0.01 0.26 ± 0.01 0.04 ± 0.01 0.22 ± 0.01 0.24 ± 0.01 0.02 ± 0.01 0.02
16:0 30.70 ± 0.16 30.86 ± 0.17 0.16 ± 0.13 30.78 ± 0.13 30.32 ± 0.13 −0.46 ± 0.15 <0.001
17:0 0.39 ± 0.01 0.40 ± 0.01 0.01 ± 0.01 0.38 ± 0.01 0.38 ± 0.01 0.00 ± 0.01 0.03
18:0 13.95 ± 0.18 13.67 ± 0.14 −0.29 ± 0.12 14.05 ± 0.12 13.83 ± 0.12 −0.22 ± 0.13 0.33
20:0 0.14 ± 0.00 0.13 ± 0.00 −0.01 ± 0.00 0.13 ± 0.00 0.12 ± 0.00 −0.01 ± 0.00 0.76
21:0 0.0128 ± 0.0037 0.0130 ± 0.0043 0.0001 ± 0.0036 0.0093 ± 0.0000 0.0147 ± 0.0000 0.0054 ± 0.0034 0.62
22:0 0.23 ± 0.01 0.22 ± 0.01 −0.01 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.00 ± 0.01 0.69
23:0 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.34
24:0 0.25 ± 0.01 0.25 ± 0.01 0.00 ± 0.01 0.25 ± 0.01 0.24 ± 0.01 −0.01 ± 0.01 0.85
Total SFAc 46.37 ± 0.17 46.36 ± 0.13 0.01 ± 0.17 46.52 ± 0.21 45.92 ± 0.15 −0.60 ± 0.21 0.006
MUFAs
18:1 cis-9 9.81 ± 0.15 9.98 ± 0.16 0.17 ± 0.15 9.99 ± 0.15 10.93 ± 0.15 0.93 ± 0.19 <0.0001
18:1 trans-9 0.08 ± 0.00 0.08 ± 0.00 0.01 ± 0.00 0.07 ± 0.00 0.17 ± 0.00 0.10 ± 0.01 <0.0001
22:1 cis-9 0.0202 ± 0.0037 0.0206 ± 0.0030 0.0004 ± 0.0045 0.0182 ± 0.0000 0.0201 ± 0.0000 0.0000 ± 0.0019 0.52
Total cis-MUFAd 11.02 ± 0.16 11.24 ± 0.17 0.21 ± 0.15 11.21 ± 0.18 12.20 ± 0.23 0.99 ± 0.20 <0.0001
Total trans-MUFAe 0.12 ± 0.00 0.12 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.23 ± 0.01 0.12 ± 0.01 <0.0001
PUFAs
18:2 n-6 22.26 ± 0.42 22.40 ± 0.37 0.14 ± 0.28 22.00 ± 0.28 22.29 ± 0.28 0.30 ± 0.29 0.87
18:3 n-6 0.08 ± 0.01 0.10 ± 0.01 0.02 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.00 ± 0.01 0.51
18:3 n-3 0.31 ± 0.02 0.31 ± 0.01 0.00 ± 0.01 0.31 ± 0.01 0.29 ± 0.01 −0.02 ± 0.01 0.58
20:3 n-6 3.07 ± 0.08 3.39 ± 0.11 0.32 ± 0.07 3.12 ± 0.07 3.17 ± 0.07 0.06 ± 0.06 0.007
20:4 n-6 9.88 ± 0.27 9.53 ± 0.22 −0.35 ± 0.13 9.77 ± 0.13 9.41 ± 0.13 −0.36 ± 0.21 0.74
20:5 n-3 1.27 ± 0.08 1.25 ± 0.06 −0.02 ± 0.07 1.24 ± 0.07 1.14 ± 0.07 −0.10 ± 0.07 0.14
22:5 n-6 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.17
22:5 n-3 0.99 ± 0.03 1.02 ± 0.02 0.03 ± 0.02 1.00 ± 0.02 0.95 ± 0.02 −0.05 ± 0.03 0.55
22:6 n-3 3.77 ± 0.16 3.39 ± 0.13 −0.37 ± 0.09 3.79 ± 0.09 3.44 ± 0.09 −0.35 ± 0.10 0.74
Total n-3 PUFAf 5.35 ± 0.23 4.96 ± 0.17 −0.39 ± 0.14 5.34 ± 0.21 4.87 ± 0.17 −0.47 ± 0.14 0.58
Total n-6 PUFAg 36.15 ± 0.34 36.30 ± 0.27 0.15 ± 0.26 35.83 ± 0.32 35.86 ± 0.33 0.03 ± 0.33 0.32
Where no bond position is listed it is unknown [40]. 20 : 4n-6 + 20 : 3n-3 co-eluted, but as 20 : 3n-3 concentration in human samples is negligible, this peak was
identified as 20 : 4n-6 [43]
aValues are given as means ± SEM
bOverall effect of treatment based on change-from-baseline was calculated by mixed model analysis, with adjustments made for fixed effects of baseline values of
the assessed variable, period, treatment, age, gender and BMI. Participant was included as a random effect
cTotal SFAs include: 11 : 0, 12 : 0, 13 : 0, 14 : 0, 15 : 0, 16 : 0, 17 : 0, 18 : 0, 20 : 0, 21 : 0, 22 : 0, 23 : 0 and 24 : 0
dTotal cis-MUFAs include: 14 : 1cis, 15 : 1cis, 16 : 1cis, 17 : 1cis, 18 : 1cis-9, 20 : 1cis, 22 : 1cis-9 and 24 : 1cis. Where no bond position is listed it is unknown, as
previously outlined in Wang et al. [43]
eTotal trans-MUFAs include: 16 : 1trans (bond position unknown) and 18 : 1trans-9 [43]
fTotal n-3 PUFAs include: 18 : 3n-3, 20 : 5n-3, 22 : 5n-3 and 22 : 6n-3
gTotal n-6 PUFAs include: 18 : 2n-6, 18 : 2trans, 18 : 3n-6, 20 : 2, 20 : 3n-6, 20 : 4n-6 + 20:3n-3, 22 : 4 and 22 : 5n-6
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interpret the FA profiles of the clusters on the score
plots. PLS-DA of the PL-FA data revealed a lack of dis-
tinction between the control and modified intervention
groups at baseline (R2Y = 0.142 and Q2 = −0.35, empir-
ical P-values R2Y: p = 0.99 (986/1000) and Q2: P = 0.76
(763/1000), suggesting that the population was indistin-
guishable with regard to PL-FA profiles prior to com-
mencement of the dietary exchange periods (Fig. 3a).
Additional file 2: Table S2 illustrates the loadings.
Following the intervention, the first component repre-
senting the maximum differentiation between the two
diets represented 5.4% of the variability in the data. The
loadings are illustrated in Additional file 2: Table S2. In
contrast to baseline, the post-intervention score plot iden-
tified a clear separation (R2Y = 0.612 and Q2 = 0.451, em-
pirical p-values R2Y: p < 0.001 (0/1000) and Q2: p < 0.001
(0/1000) in PL-FA profiles of participants when they were
assigned to the modified and control intervention diets
(Fig. 3b). The FAs that mainly contributed to this dietary
status separation were: 18 : 1trans-9, 16 : 1trans, 18 : 1cis-
9, that were higher following the modified diet, while 16 :
0, 14 : 1 cis, 14 : 0, 15 : 0 and 20 : 3n-6 were higher follow-
ing the control diet.
Discussion
The food-exchange model was used for the implementa-
tion of two iso-energetic high-fat, high-dairy diets vary-
ing in FA composition in the RESET study, through the
use of SFA-reduced, MUFA-enriched dairy products and
control alternatives with a FA profile typical of retail
dairy products. Specific dietary targets following treat-
ments were largely achieved in a free-living population
at moderate risk of CVD. Analysis of weighed dietary re-
cords confirmed that it was possible to lower the mean
SFA intake by 2.5%TE and increase MUFA intake by
3.7%TE following the diet containing modified dairy
Fig. 2 Change-from-baseline in the plasma phospholipid profile of SFA: 16 : 0 (a) and MUFAs: 18 : 1cis-9 and 18 : 1trans-9 (b) following 12-week
diets that incorporated control and modified dairy products. Values are means ± SEM, n = 54. Significance shown as * p <0.001, ** p < 0.0001
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products compared with the control products. Previ-
ously, Noakes et al. reported differences of 2.2%TE SFA
and 2.8%TE MUFA (described as oleic acid intake only)
following consumption of dairy products that were pro-
duced following a protein-encapsulated lipid (rapeseed
and soybean oil) bovine supplementation period, when
compared to control dairy foods [47]. There was a sig-
nificant difference in recorded SFA intake between inter-
ventions in our study, however the reduction in SFA
intake following the modified diet was slightly less than
predicted by our food-exchange model. Compliance was
further confirmed by assessment of dietary tick-sheet
records.
To our knowledge, this is the first human study to as-
sess the impact of modified milk, cheese and butter con-
sumption on PL-FA concentrations, in comparison to
control dairy products with a FA profile typical of retail
products. In line with previous findings [31, 48–50], ob-
jective dietary compliance was confirmed by assessment
of PL-FA profiles, with consumption of the control and
modified dairy products leading to differential effects on
total plasma phospholipid SFAs and MUFAs and their
sub-classes. The consumption of the SFA-reduced,
MUFA-enriched dairy products led to a small decrease
in the abundance of total SFAs, and increases in total
cis-MUFAs, including 18 : 1cis-9 in the PL-FA profile,
when compared to the control products. These changes
are comparable to the proportion of PL-FA total SFAs
and MUFAs observed in the DIVAS study following a
16-week MUFA-rich diet (9%TE SFA; 19%TE MUFA;
4%TE n-6 PUFA) [31]. Previous literature has suggested
that SFAs and MUFAs with even numbered carbon chain
length can be endogenously synthesised by humans and
may be less affected by dietary intake [51]. Hodson et al.
suggested that this may be because it is difficult to alter
the proportion of FAs that are already relatively abundant
in the diet and that increases in SFA intake are not
reflected in increases in the plasma FA profiles [30]. How-
ever, changes in PL-FA concentrations observed in the
RESET study mirrored the FA composition of our inter-
vention dairy foods [52]. PLS-DA provided a means for
visualizing adherence to a dietary intervention. Despite
using a relatively homogenous population and a modest
dietary exchange, our PLS-DA plot highlighted some dis-
tinction between the PL-FA profile of the participants fol-
lowing the modified and control dietary exchange periods,
suggesting a small but significant response to our inter-
vention. This analysis only explained approximately 5% of
the overall variability in our dataset but the affected FAs,
including 18 : 1trans-9 and 18 : 1cis-9 and 16 : 0, were
relevant to our interevntions. Furthermore, it provided
further evidence that PL-FA were illustrative of short to
medium-term FA intake [29–31].
Supplementation of the dairy cow diet with unsatur-
ated FA leads to increased levels of ruminant trans-fatty
acids (rTFA) in the milk and dairy products, through ru-
minal biohydrogenation of unsaturated FA [15, 25, 27].
There was a calculated dietary increase of 1.3%TE in
Fig. 3 Orthogonal PLS-DA, score plots at baseline (a) and post-intervention (b) calculated using plasma phospholipid FA concentrations in adults
at moderate risk of cardiovascular disease (n = 54). FA, fatty acid; PLS-DA, partial least squares discriminant analysis
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total TFA intake following the modified, when compared
with the control diet. It was not possible to quantify our
participants’ voluntary intake of specific TFA isomers
(i.e. ruminant or industrial TFA intake) from weighed
dietary records using our nutrient analysis software. How-
ever, based on the differences in TFA composition be-
tween our control and modified dairy products [52], it is
apparent that the majority of the increased TFA intake re-
corded following the modified diet was derived from ru-
minant sources. In contrast to the recognised detrimental
impact of industrially-produced TFA on cardiovascular
health, consumption of rTFA may not be adversely linked
to CVD risk [53], except possibly at high intakes [54, 55].
It should be noted that the calculated dietary TFA intake
following our modified intervention (2.5 ± 0.1%TE)
exceeded the recommended population maximum of 2%
food energy [3] which does not discriminate between
ruminant and industrial sources, and is higher than the
current mean TFA intake in UK adults (0.5%TE and 0.5%
food energy) [4]. This may be in part explained by the high
dairy fat content of our intervention diets. In support of
this we also observed that consumption of the SFA-
reduced, MUFA-enriched dairy products lead to signifi-
cant increases in total trans-MUFA and 18:1 trans-9
concentrations in the PL-FA. Whilst our PL-FA analysis
approach was unable to identify specific trans isomers
other than 18:1 trans-9 [43], the detailed FA analysis of
the dairy foods used in the RESET study (Kliem KE,
Humphries DJ, Markey O, Vasilopoulou D, Fagan CC,
Grandison AS, Todd S, Givens DI, Lovegrove JA: Food
chain approach to lowering saturated fat in milk and dairy
products: the RESET study, submitted) suggest there was
likely to be a complex mixture of TFA in the phospholipid
pool. It may be that feeding strategies that limit increases
of TFA in milk fat following bovine supplementation with
plant oils, such as the use of encapsulation protection
technology may be advantageous [27, 56]. However,
further work is justified to determine whether rTFA are
detrimental to cardiovascular health [27].
Our intervention presented some challenges. Our
bovine supplementation strategy was successful in alte-
ring the FA profile of the milk [52]. Alongside this, we
observed a depression in milk fat content following
supplementation of the bovine diet with high-oleic
sunflower oil which has been reported previously [57].
As a result of this, it was necessary to standardise the fat
content of the raw control milk prior to UHT so that it
was equivalent to that of the modified milk. Further-
more, our modified cheese had a lower fat content
compared with conventional cheese and it was necessary
for our participants to consume an additional 3.6 g/d of
butter during the modified dietary exchange period to
standardize the fat intake of the two intervention
periods.
A challenge faced by some participants was incorpor-
ating sufficient quantities of products, especially cheese,
into their habitual diets on a daily basis. In line with re-
cent NDNS data [4], some of our participants were not
accustomed to consuming the quantities of dairy prod-
ucts that were prescribed in our food-exchange model
(unpublished data obtained by food frequency question-
naire). Although it was not logistically feasible for us to
include a wider range of dairy products in the RESET
study, it is possible that a greater variety of items may
have reduced the likelihood of ‘product boredom’ and
minimized the potential for compliance issues [58].
Compliance with the dietary exchange was cited as the
main reason for dropout by nine of our participants,
predominantly in the early stages of the intervention. It
should be noted that a similar number of participants
withdrew from the modified and control dietary ex-
change periods, suggesting that the two regimens were
equal in terms of acceptability. For those who completed
the study, our tick-sheet records suggested that compli-
ance to the dietary regimens was excellent and our PL-
FA data provided further objective evidence of dietary
adherence. It is acknowledged that there may have been
discrepancies in tick-sheet recordings as a result of ‘de-
sirability bias’, i.e. participants may have recorded the
portions that they were required to eat as opposed to
what they had actually consumed [58], and this may
have led to more modest differences in PL-FA profiles
between the two dietary exchange periods.
We observed a moderately high amount of under-
reporting assessed by EI at baseline, however, this was
similar to that observed in previous free-living populations
[31, 59]. A high proportion of participants (61%; n = 33) in
the RESET study were classified as overweight (BMI
of ≥ 25.0 kg/m2). It is recognized that overweight or
obese individuals may be more prone to selective bias
and omission of foods with a negative health image,
leading to potential under-reporting of dietary intake
[60]. We observed a lower degree of under-reporting
following the intervention, when our replacement model
predicted that the dairy products would contribute to over
25% of daily EI. It could be speculated that participants
had a greater appreciation of the importance of giving an
accurate account of their dietary intake whilst on the
intervention. The present study has illustrated that
through the incorporation of dairy products with an al-
tered FA profile into the habitual diet, it was possible for
free-living participants to successfully improve their diet-
ary fat quality. This was in agreement with previous suc-
cessful food-exchange models [31, 35, 58]. Our dietary
interventions were designed to contain a high quantity of
dairy fat (~41 g/d). Both intervention periods increased
relative intake of total fat and SFA over baseline. However,
it is feasible that a similar, but more moderate, approach
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could be used for assisting in the reduction of dairy
SFA intake at a population level, without reducing
dairy consumption. Furthermore, we have previously
reported that consumers generally accepted the SFA-
reduced, MUFA-enriched dairy products, when tasted
in a blinded manner (Markey O, Souroullas K, Fagan
CC, Kliem KE, Vasilopoulou D, Jackson KG, Humph-
ries DJ, Grandison AS, Givens DI, Lovegrove JA,
Methven L: Consumer acceptance of dairy products
with a saturated fatty acid-reduced, monounsaturated
fatty acid-enriched content, In Review).
Conclusions
We sucessfully implemented a high-fat, high-dairy food-
exchange model that was suitable for replacing dairy
products with a FA profile typical of retail products with
SFA-reduced, MUFA-enriched alternatives over a 12-
week period in a free-living population at moderate risk
of CVD. Changes in the dietary intake of SFA and
MUFA between our interventions was confirmed by
changes in the concentrations of these FAs in the plasma
phospholipid fraction, indicative of adherence to our
dietary intervention.
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